Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

NCT01223235 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Fallopian Tubes Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions

BIOLOGICAL: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]